Cidara Therapeutics and Mundipharma Announce Positive Toplin

For Trade and Medical Media Only Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor

Related Keywords

China , California , United States , San Diego , Japan , Canada , America , Patrick Bursey , Brian Sheehan , Jan Milton Edwards , George Thompson , Asia Pacific , Jeffrey Stein , Brian Ritchie , University Of California , Community Register , School Of Medicine , Cidara Therapeutics Inc , European Commission , Drug Administration , Nasdaq , Exchange Commission , Us Food Drug Administration , Lifesci Communications , European Medicines Agency , Securities Exchange , For Trade , Medical Media Only , New Drug Application , Marketing Authorization Application , Cause Mortality , Invasive Candidiasis , Qualified Infectious Disease Product , Fast Track , Orphan Drug Designation , Cidara Therapeutics , Latin America , Pain Management , Infectious Disease , Consumer Healthcare , Looking Statements , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Quarterly Report , Search Orphan Drug Designations , Sci Advisors , Sci Communications , Cidara , Herapeutics , Mundipharma , Nnounce , Positive , Topline , Results , Rom , Lobal , Hase , Pivotal , Restore , Trial , Ezafungin , Treatment , Candidemia , Nvasive , Candidiasis ,